Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_734_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Disclaimer
- •Contents
- •Contributors
- •Embryology
- •Lymphatics
- •Nerves
- •Clinically Relevant Anatomic Variations
- •Duodenum Inversum
- •Pancreas Divisum
- •Annular Pancreas
- •Ectopic Pancreas
- •Ansa Pancreatica
- •Pancreaticobiliary Maljunction
- •Duplication Anomalies
- •Physiology
- •Duodenal Physiology
- •Mechanical Function
- •Endocrine Function
- •Pancreatic Physiology
- •Exocrine Physiology
- •Normal Anatomy
- •Duodenal Anatomy
- •Pancreatic Anatomy
- •Ductal Anatomy
- •Vasculature
- •Endocrine Physiology
- •References
- •Etiology
- •Pathophysiology
- •Diagnosis
- •Clinical Presentation
- •Laboratory Tests
- •Imaging
- •Medical Management
- •Fluid Resuscitation
- •Analgesics
- •Prophylactic Antibiotics
- •Nutrition
- •Complications
- •Long-Term Sequelae of Acute Pancreatitis
- •References
- •Introduction
- •Initial Treatment
- •Reducing Severity of Acute Pancreatitis
- •Fluid Resuscitation
- •Pain Management
- •Nutrition
- •Preventing Infectious Complications
- •References
- •Introduction
- •Sterile Pancreatic Necrosis
- •Antibiotic Therapy
- •Catheter Drainage
- •Video-Assisted Retroperitoneal Drainage (VARD) Procedure
- •Sinus Tract Necrosectomy
- •Open Necrosectomy
- •Open Trans-Gastric Cystogastrostomy
- •Disconnected Distal Pancreatic Duct Syndrome
- •Introduction
- •References
- •Introduction
- •Venous Thrombosis
- •Intra-Abdominal Hypertension
- •Thoracic Complications
- •Gastrointestinal Complications
- •References
- •Pain
- •Endocrine Dysfunction
- •Exocrine Dysfunction
- •Conclusion
- •References
- •Background
- •Postoperative Care
- •References
- •Background
- •Head-Dominant Disease
- •Tail-Dominant Disease
- •Perioperative Management
- •Procedure Steps
- •Open Whipple
- •MIS Whipple
- •Open Distal Pancreatectomy
- •MIS Distal Pancreatectomy
- •Pearls
- •References
- •Introduction
- •Procedures
- •Indications
- •Contraindications
- •Preoperative Workup
- •Pediatrics
- •Patient Selection
- •Contraindications
- •Key Steps
- •Common Steps
- •Pitfalls/Tricks
- •Local Complications
- •Systemic Complications
- •References
- •History/Introduction
- •Indications
- •Adults
- •Procedural Aspects
- •Preoperative Care
- •Total Pancreatectomy
- •Islet Infusion
- •Minimally Invasive Surgery (MIS)
- •Postoperative Care
- •Outcomes
- •Perioperative Data
- •Perioperative Complications
- •Endocrine Function
- •References
- •Introduction
- •Duodenal Adenomas
- •Duodenal Adenocarcinomas
- •Duodenal Neuroendocrine Tumors (D-NETs)
- •Other Non-neoplastic Epithelial Lesions
- •Duodenal Gastrointestinal Stromal Tumors (DGISTs)
- •Leiomyoma
- •Lipoma
- •Choledochal Cysts
- •Duodenal Lymphoma
- •Conclusion
- •References
- •Introduction
- •Pre-procedural Considerations
- •Indications
- •Resection Techniques
- •Sporadic Non-ampullary Adenomas: Cold Snare Polypectomy
- •Sporadic Non-ampullary Adenomas: EMR
- •Sporadic Non-ampullary Adenomas: ESD
- •Sporadic Non-ampullary Adenomas: Full-Thickness Resection Device
- •Ampullary Adenomas: Endoscopic Papillectomy
- •Sporadic Non-ampullary Adenomas: Cold Snare Polypectomy
- •Sporadic Non-ampullary Adenomas: EMR
- •Endoscopic Papillectomy
- •Surveillance
- •References
- •Introduction
- •Benign Tumors
- •Genetic Syndromes
- •Pre-Malignant Tumors
- •Low-Grade Malignancies
- •Alternatives
- •Inclusion Criteria
- •Preoperative Planning
- •Open Transduodenal Ampullectomy
- •Minimally Invasive (Robotic-Assisted) Transduodenal Ampullectomy
- •Outcomes
- •Conclusions
- •References
- •Introduction
- •Anatomy
- •Laparoscopic Segmental Duodenectomy
- •Robotic Segmental Duodenectomy
- •Technique
- •Open Segmental Duodenectomy
- •Patient Positioning
- •Technique
- •Conclusion
- •References
- •Overview
- •Intraductal Papillary Mucinous Neoplasm (IPMN)
- •General Concepts
- •Novel Biomarkers
- •DNA-Based Biomarkers
- •MiRNA
- •Protein-Based Biomarkers
- •IPMNs
- •MCNs
- •SCNs
- •SPTs
- •Guidelines
- •Surveillance Discontinuation
- •Follow-Up Strategy
- •The Verona Policy
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Work-Up
- •Tissue Diagnosis
- •Serum Tumor Markers
- •Multidisciplinary Decision-Making
- •Adjuvant Trials
- •Systemic Chemotherapy
- •Chemoradiation
- •Neoadjuvant Trials
- •Chemotherapy
- •Chemoradiation
- •Pancreatectomy
- •Summary
- •References
- •Introduction
- •Diagnosis
- •Imaging
- •Functionality
- •Insulinoma
- •Gastrinoma
- •VIPoma
- •Glucagonoma
- •Staging/Surgical Decision-Making
- •Nonmetastatic Disease
- •Metastatic Disease
- •Multidisciplinary Decision-Making
- •Surgical Resection
- •Systemic Treatments
- •Open Trials
- •Surveillance
- •References
- •Renal Cell Carcinoma
- •Introduction/Epidemiology
- •Diagnosis/Radiology/Pathology
- •Treatment/Outcome
- •Colorectal Carcinoma
- •Introduction/Epidemiology
- •Diagnosis/Radiology/Pathology
- •Treatment/Prognosis
- •Melanoma
- •Introduction/Epidemiology
- •Diagnosis/Radiology/Pathology
- •Treatment/Prognosis
- •Sarcoma
- •Introduction/Epidemiology
- •Diagnosis/Radiology/Pathology
- •Treatment/Prognosis
- •Conclusion
- •References
- •Preoperative Considerations
- •Key Steps
- •Staging Laparoscopy
- •Specimen Removal
- •Vascular Resection
- •Reconstruction
- •Pancreaticojejunostomy
- •Hepaticojejunostomy
- •Gastro- or Duodeno-Jejunostomy
- •Final Steps
- •References
- •Randomized Controlled Trials
- •Surgical Technique
- •Resection Phase
- •Reconstruction Phase
- •Postoperative Course
- •Conclusions
- •References
- •Introduction
- •Preoperative Workup
- •Preoperative Planning
- •Surgical Management
- •Patient Preparation
- •Surgical Steps
- •Step 1: Kocher Maneuver
- •Step 4: Pancreatic Transection
- •Reconstruction
- •Hepaticojejunostomy
- •Pancreaticojejunostomy
- •Duodenojejunostomy
- •References
- •Introduction
- •Preoperative Planning
- •Diagnostic Laparoscopy
- •Radical Antegrade Modular Pancreatosplenectomy (RAMPS)
- •Splenic Vein Stump Length
- •Ligamentum Teres/Falciform Pedicle Flap
- •References
- •History
- •Early Exploration
- •Trends Over Time
- •Morbidity
- •Safety
- •Oncologic Safety
- •Preoperative Planning
- •Clinical Considerations
- •Anatomical Considerations
- •Surgical Technique
- •Conclusion
- •References
- •Introduction
- •Indications
- •Preoperative Testing
- •Operative Approach
- •Peritoneal Access
- •Specimen Extraction
- •Closure
- •Clinical Outcomes
- •Conclusions
- •References
- •Introduction
- •Preoperative Preparation
- •Key Shared Operative Steps
- •Trocar Placement
- •Splenic Flexure Mobilization
- •Pancreas Mobilization
- •Identify Pancreatic Pathology
- •Pancreatic Transection
- •Splenic Vein Dissection
- •Splenic Artery Dissection
- •Conclusion
- •References
- •Introduction
- •Historical Evolution
- •Perioperative Outcomes
- •Oncologic Outcomes
- •Neoadjuvant Therapy
- •Preoperative Adjuncts
- •Preoperative Coiling
- •Aortic Stenting
- •Robotic DP-CAR Surgical Technique
- •Positioning
- •Port Placement
- •Surgical Steps
- •Perioperative Care
- •Conclusion
- •References
- •Introduction
- •Preoperative Considerations
- •Laparoscopic Enucleation
- •Patient Positioning
- •Procedure
- •Robotic Enucleation
- •Patient Positioning
- •Procedure
- •Open Enucleation
- •Postoperative Management
- •Postoperative Outcomes
- •References
- •Introduction
- •Indications
- •Preoperative Assessment
- •Serologic Testing
- •Surgical Management
- •Patient Preparation
- •Diagnostic Laparoscopy
- •Surgical Steps
- •Step 1: Gastric Mobilization
- •Step 2: Pancreatic Resection
- •Step 3: Reconstruction
- •Jejunojejunostomy
- •Pancreaticojejunostomy
- •Discussion
- •References
- •Introduction
- •Biliary Obstruction
- •Endoscopic Interventions
- •Plastic Versus Metal Stents
- •Covered Versus Uncovered Metal Stents
- •Stent Obstruction
- •Surgical Options
- •Endoscopic Versus Surgical Intervention
- •Duodenal Obstruction
- •Duodenal Stents
- •Venting Percutaneous Gastrostomy Tubes (PEG)
- •Surgical Gastrojejunostomy (Duodenal Bypass)
- •Endoscopic Versus Surgical Intervention
- •Abdominal Pain
- •Celiac Plexus Neurolysis
- •Surgical Celiac Plexus Block
- •Summary
- •References

10 Total Pancreatectomy withIslet Cell Autotransplantation
161
Procedural Aspects
Preoperative Care
Prophylactic perioperative antibiotics according to local protocol are administered.
Total Pancreatectomy
There are several surgical variations to the total pancreatectomy and biliary and
gastrointestinal reconstruction.
Removal of the pancreas as a single specimen vs. two sections is dependent on
institutional preference, degree of pancreatic inammation and brosis, and prior
decompression or resection procedures.
Splenic preservation is of interest, yet associated splenic vein thrombosis,
densely adherent splenic vessels in advanced forms of chronic pancreatitis, and the
critical need to avoid prolonged warm ischemia time, limits most attempts at splenic
preservation. In our institution, about 70% undergo splenectomy [16], but in one of
the largest multicenter TPIAT consortiums (Prospective Observational Study of
TPIAT, POST), 95% of adult and 100% of children have undergone splenectomy [10].
Our institution does not preserve the pylorus. Our research has demonstrated that
the pylorus preserving technique has a higher rate of long-term complications, up to
55% compared to 15% of the classic technique, particularly due to marginal ulceration [16]. It is also of importance to preserve the coronary vein, which will remain
as the only venous drainage of the stomach, and its sacrice could lead to venous
congestion, gastric ischemia, or delayed gastric emptying.
It is imperative to limit warm ischemia time, with ligation of the vascular ow of
the pancreas only after complete mobilization and preparation for removal. Precise
hemostasis in anticipation for full heparinization at the time of islet cell infusion
must also be performed. The gastroduodenal artery (GDA) is test-clamped to conrm preservation of ow to the hepatic proper artery and is only ligated immediately prior to nal dissection of the uncinate process and specimen removal.
Various approaches to gastrointestinal and biliary reconstruction have been
described. At our institution, the jejunum is brought behind the mesenteric vessels
through the aortomesenteric window to lie in the position of the native duodenum
and an end-to-side hepaticojejunostomy with interrupted 4–0 polydioxanone suture
(PDS) is created. An antecolic end-to-side loop gastrojejunostomy is then created
with an inner layer of running 3–0 PDS and outer layer of 3–0 silk.

162
J. Chang et al.
After completion of the gastrointestinal reconstruction, the fascia and skin are
closed, and the patient is taken to the post-anesthesia care unit (PACU) intubated on
a continuous insulin infusion for a planned reopening of recent laparotomy and islet
infusion once islet cell isolation and purication is completed.
Islet Cell Isolation, Purication
Our institution successfully performs islet cell isolation with remote processing at a
location 2h drive time away. Once the pancreas is removed, the surgeon ushes the
organ via the splenic artery and GDA with the University of Wisconsin or histidinetryptophan-ketoglutarate (HTK) solution, both of which are commonly used for
solid organ perseveration, for cold preservation prior to transportation. We believe
that lack of onsite or local islet-processing facility should not be a barrier to TPIAT
and have comparable outcomes in terms of islet yield and postoperative insulin
independence [17]. There is an 8–10h total time lapse between complete removal
of specimen and islet infusion at our institution. Other institutions have reported up
to 48h intervals between specimen removal and islet infusion.
The pancreas undergoes enzymatic with collagenase and proteinase and mechanical digestion via the Ricordi digestion isolation changer to yield islet isolates [18].
To initiate tissue digestion and dissolution, collagenase and proteinase are infused
under pressure into the main pancreatic duct to distend the intact gland. After disruption, the pancreas is sectioned and placed in a Ricordi digestion isolation chamber for gentle mechanical dispersion until the islets are separated from acinar tissue
as detected by microscopic analysis with dithizone staining. The extent of islet purication is imprecise as a balance must be achieved between purifying the islets
away from surrounding tissue (to reduce the volume of the infusate and minimize
thrombogenic particulate matter) while preserving the absolute number of islets
with each successive purication cycle. Purication is achieved through continuous
density gradient centrifugation. Final islet counts can be determined using an automated islet counter or standard manual counting methods, commonly reported as a
standardized islet equivalent and islet equivalent per kilogram of body weight. One
islet equivalent is equal to the volume of an islet with a diameter of 150μm. Mean
islet yield from large case series are listed in Table 10.2. Before transplant, islet
preparations are suspended in a 50:50 solution of 20% human serum albumin and
transplant media with antibiotics solution, such as ciprooxacin. Although there is
bacterial contamination from the attached duodenum, there is no clinical benet to
routinely culture this islet preparation. In our retrospective analysis, up to 65% of
patients will have positive intraoperative cultures with no difference in infectious
complication rate [19].

10 Total Pancreatectomy withIslet Cell Autotransplantation
Islet Infusion
163
In our institution, a re-exploratory laparotomy is performed to conrm hemostasis
and examine the biliary and gastrointestinal reconstruction. The portal system can
be accessed through the catheterization of the splenic vein, mesenteric vein, umbilical vein in the falciform ligament, or transhepatic direct portal puncture. Our institution typically accesses the splenic vein remnant with a 10-gauge angiocatheter
secured with a suture. If the splenic vein remnant is not appropriate, a mesenteric
vein such as the inferior mesenteric vein is used. The superior mesenteric vein is a
less preferred option as it requires oversewing of the site of venipuncture with 5–0
permanent monolament suture. A transjugular intrahepatic portosystemic shunt
(TIPS) performed by interventional radiology has also demonstrated to be a viable
option while preserving portal vein pressure in our limited experience with liver
transplant patients. Other institutions have also reported portal vein infusion via
percutaneous transhepatic cannulation of the portal system, avoiding the need for a
relaparotomy. The absolute volume of islets that can be delivered via intraportal
infusion is dependent on the size of the liver and the degree of steatosis. Portal vein
pressures are checked periodically with a manometer and if it reaches 25cm H
2
O,
the infusion is stopped, and the remaining islets are placed in the peritoneal cavity.
The major complications of portal access are portal hypertension and portal vein
thrombosis. Weight-based systemic therapeutic heparinization with an initial bolus
dosage of 60–70units per kg is initiated immediately prior to islet infusion. Our

164
J. Chang et al.
research has demonstrated that there are no statistically signicant differences in
postoperative hemorrhage rates when compared by rates of lower (<60units per kg)
and higher (≥60units per kg) rates of heparin dosing [19]. Prophylactic anticoagulation is continued postoperatively to help prevent portal vein thrombosis and platelet aggregation. Other current methods to reduce these complications include
limiting the volume and rate of infusion and administering dextran for 48h after
surgery to decrease the inammatory reaction in children [20].
Minimally Invasive Surgery (MIS)
The case complexity and need to minimize warm ischemia time has limited minimally invasive techniques for TPIAT.Publications on all the components of TPIAT
(total pancreatectomy, gastrointestinal reconstruction, and AIT) are restricted to
limited case series.
At Johns Hopkins University, about 60% of TPIAT operations are performed
laparoscopically or laparoscopically assisted with an operative room equipped with
an islet isolation laboratory for immediate processing [21]. They sequentially resect
the pancreas into two stages—rst the head and then the body and tail, which is
extracted via the periumbilical 12mm port. The hepaticojejunostomy is performed
using a single layer of running 4–0 barbed sutures [22]. The gastrojejunal anastomosis is performed antecolic, retrogastric along the posterior wall of the stomach
with a laparoscopic stapler in a side-to-side technique. Occasionally, a Braun jejunojejunostomy will be created to reduce bile reux.
Once islet cells are ready for autotransplantation into the liver, a 15-gauge needle
placed through a port site is guided into the portal vein. Once completed, the needle
is removed, and direct pressure is applied to the site of the portal vein for hemostasis.
Most published literature regarding robot-assisted TPIAT are limited case reports
[23]. There is one published series on robot-assisted TPIAT from the University of
Arizona with six patients. Their technique is summarized below [24]. The University
of Pittsburgh has published a successful case series on the robotic total pancreatectomy, including one case with TPIAT [25]. In the most recent ongoing POST consortium, 7% of adult TPIAT are performed robot-assisted, although their full data is
yet to be published [10].
In the University of Arizona group, the pancreatic dissection is started from distal pancreas towards the head, dividing the splenic artery and vein distal to the
pancreatic tail to aid the dissection of the body and the tail off the retroperitoneum,
then dissection of the superior mesenteric vein, portal vein, and splenic vein conuence. A Kocher maneuver is then performed to mobilize and subsequently divide
the duodenum and the pancreatic head, which is removed en-bloc via a Pfannenstiel
incision. The hepaticojejunostomy is created over a 5 French stent with running 4–0

10 Total Pancreatectomy withIslet Cell Autotransplantation
165
PDS sutures and the duodenojejunostomy is created with running 3–0 absorbable
barbed sutures for the internal layer and running 3–0 nonabsorbable barbed sutures
for the external layer. A stapled Braun jejunojejunostomy is created. A 14-gauge
laparoscopic needle is inserted into the splenic vein (SV) stump. After completion
of the infusion, the SV stump is double clipped.
There is institutional variation in the methods of islet infusion. Some centers may
choose to use the inferior mesenteric vein or another colic vein branch; others have
described performance of the islet infusion on the following day utilizing a transjugular approach into the hepatic veins or a percutaneous transhepatic portal vein
infusion with the assistance of interventional radiology.
Postoperative Care
Patients are transferred to the intensive care unit (ICU) after surgery with a continuous insulin infusion, extubated the next morning, and subsequently transferred out
of the ICU within 24h on a standardized sliding scale algorithm with assistance
from the endocrinology service. They are discharged on a basal bolus regimen to
decrease the metabolic burden on the transplanted islets and allow for proper
engraftment and revascularization.
All patients at our institution have a 10 French bridled nasojejunal feeding tube
placed intraoperatively and are started on enteral feeds on postoperative day 1,
which are continued until the patient demonstrates adequate oral intake.
Patients are also continued on deep vein thrombosis (DVT) prophylaxis while
inpatient and discharged home on aspirin depending on the level of thrombocytosis
from the splenectomy. Proton pump inhibitors are prescribed upon discharge for at
least 3months to prevent marginal ulceration and metoclopramide for 2weeks to
promote gastric motility. A taper to insulin independence is initiated in the outpatient setting with endocrinology.
The median postoperative length of stay is reported to be around 9–11days for
adults and 15days for children [10, 16].
Lifelong pancreatic enzyme supplementation is required and annual nutritional
monitoring for steatorrhea, body composition, and fat-soluble vitamins (A, D, and
E), along with bone density is recommended.
Patients continue frequent follow-up with their endocrinologist for the rst year
after TPIAT, with eventual transition to annual testing for diabetes which includes
fasting plasma glucose, hemoglobin A1C, and c-peptide levels. These variables
combined with ongoing insulin requirements compromise of the BETA-2 Score
which could be used to assess graft function [26].

166
J. Chang et al.
Outcomes
Perioperative Data
Operative variables of mean operative time, estimated blood loss, and length of stay
are listed in Table 10.1 comparing select studies on the open, laparoscopic, and
robotic approach.
Perioperative Complications
TPIAT has one of the highest intrinsic complication rates of any elective operation.
Immediate operative mortality has been reported to be 0–6% [11, 18]. Morbidity up
to 50% has been described, with most commonly reported complications to be
pneumonia, delayed gastric emptying, deep venous thrombosis, bleeding, and
wound infection [16, 18, 19]. Thirty-day readmission rates range up to 25%, with
the most common reason being surgical site infection and gastrointestinal issues
(such as small bowel obstruction and delayed gastric emptying) [19]. Up to a 10%
reoperative rate within 30days of TPIAT has been reported, most commonly for
bleeding [10]. Despite the risks of hemorrhage associated with this procedure, there
is a complex coagulation and pro-inammatory interface which increases thrombosis risk in these patients, due to the known smoldering inammatory state that
increases venous thromboembolism risk in chronic pancreatitis patients [29], major
operation with risk of signicant blood loss, and the instant blood-mediated inammatory reaction with direct exposure of islets to plasma [20]. A complication specic to this procedure is portal vein thrombosis (PVT), which has been described in
up to 10% in adults [10]. Some institutions such as the University of Minnesota
routinely screen their patients for PVT with ultrasound within the rst week of
transplant [30], while ours does not.
Table 10.1 Perioperative data
Open Laparoscopic Robotic
Study sample size 112 195 20 6
Mean operative time
(min)
Mean estimated blood
loss (mL)
Mean length of stay
(days)
Citation (year) Wilson (2014)
544 240 493 717
548.8 589 627.5 630
14 9 11 12.6
[27]
Morgan (2018)
[15]
Fan (2017)
[28]
Galvani (2014)
[24]

10 Total Pancreatectomy withIslet Cell Autotransplantation
167
Endocrine Function
Most series report insulin independence in 20–40% of patients at 1–3years with
manageable insulin requirements for the remainder of patients [7, 11, 31, 32]. These
results are summarized in Table10.2. The number of islet equivalent per kilogram
transplanted is the strongest predictor for insulin independence [31, 33, 34]. The
incidence between obesity and insulin resistance is a known correlation, and it has
been demonstrated that an absolute weight of 78kg or a BMI greater than 28 may
have an increased chance of requiring long-term insulin supplementation in TPIAT
patients [31].
Unfortunately, the function of transplanted islet grafts will decline over time.
This decrease in function is partially attributed to the proven immediate inammatory response, termed instant blood-mediated inammatory reaction, when islets
are exposed to blood, along with islet hypoxia which leads to islet apoptosis [20,
35]. Research into alternative low inammatory reaction transplant sites such as the
omentum, muscle, and bone marrow as well as adjuvant agents such as tumor necrosis factor (TNF) blockers are ongoing [36].
Pain andQuality ofLife
Multiple studies have demonstrated the reduction of pain in these patients. About
50% of patients are able to be independent from opioids 1year after surgery, summarized in Table10.3 below [7, 27, 33, 34]. Pain, per patient reported outcomes,
persists or recurs in about 10–20% of patients after TPIAT [5, 37].
Overall, patients report improvements in their perceived physical and mental
health, as measured by patient reported outcome surveys, with some institutions
reporting up to 92% of patients reporting an overall improvement in health [15, 27,
34], and 60–70% improvement in depression and anxiety although improvement in
Table 10.2 Islet yield and glucose control following TPIAT
Center
Study sample size 215 112 195 75
Mean age (years) 35.7 37.3 40.3 13.8
Mean islet yield
(IEG/kg)
Insulin independence
1year after TPIAT
Insulin independence
5years after TPIAT
Citation (year) Bellin (2019)
University of
Minnesota
3488 6027 3253 N/a
27.0% 38% 29% 37%
22.3% 27% 23% N/a
[34]
University of
Cincinnati
Wilson (2014)
[27]
Medical University
of South Carolina
Morgan (2018)
[15]
University of
Minnesota
Chinnakotla
(2014) [7]

168
Table 10.3 Pain control following TPIAT
Center
Study sample size 215 112 195
Preoperative mean oral
morphine equivalents
(MEQ/d)
Mean oral morphine equivalents
1year after TPAIT
(MEQ/d)
Narcotic independence 1year
after TPIAT
Narcotic independence 5year
after TPIAT
Citation (year) Bellin (2019)
University of
Minnesota
N/a 118.9 208
N/a 74.1 60
46% 55% N/a
63% 73% N/a
[34]
University of
Cincinnati
Wilson (2014)
[27]
Medical University of
South Carolina
Morgan (2018) [15]
J. Chang et al.
quality of life is not always associated with decreased opioid use [37]. The need to
start insulin also has not been associated with a lower quality of life [38]. However,
to provide consistency in reporting this data varies, and to address these critical
research gaps, a multicenter research consortium called POST was started on 2017
to prospectively collect data about pain, quality of life, glycemic control, and costeffectiveness in patients undergoing TPIAT [10].
References
1. Schnelldorfer T, Adams DB, Warshaw AL, Lillemoe KD, Sarr MG. Forgotten pioneers of
pancreatic surgery: beyond the favorite few. Ann Surg. 2008;247(1):191–202.
2. van Heerden JA.The rst total pancreatectomy. Am J Surg. 1986;151(2):197–9.
3. Jahansouz C, Jahansouz C, Kumer SC, Brayman KL.Evolution of β-cell replacement therapy
in diabetes mellitus: islet cell transplantation. J Transp Secur. 2011;2011:247959.
4. Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, etal. Total
or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis.
Ann Surg. 1980;192(4):526–42.
5. Bellin MD, Freeman ML, Gelrud A, Slivka A, Clavel A, Humar A, etal. Total pancreatectomy
and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest.
Pancreatology. 2014;14(1):27–35.
6. Pasricha PJ.Unraveling the mystery of pain in chronic pancreatitis. Nat Rev Gastroenterol
Hepatol. 2012;9(3):140–51.
7. Chinnakotla S, Bellin MD, Schwarzenberg SJ, Radosevich DM, Cook M, Dunn TB, etal.
Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indication, surgical techniques, postoperative management, and long-term outcomes. Ann Surg.
2014;260(1):56–64.
8. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J, etal. Hereditary
pancreatitis and the risk of pancreatic cancer. International hereditary pancreatitis study group.
J Natl Cancer Inst. 1997;89(6):442–6.

10 Total Pancreatectomy withIslet Cell Autotransplantation
9. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, etal. Type
3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.
Lancet Gastroenterol Hepatol. 2016;1(3):226–37.
10. Nathan JD, Yang Y, Eaton A, Witkowski P, Wijkstrom M, Walsh M, etal. Surgical approach and
short-term outcomes in adults and children undergoing total pancreatectomy with islet autotransplantation: a report from the prospective observational study of TPIAT. Pancreatology.
2022;22(1):1–8.
11. Sutherland DER, Radosevich DM, Bellin MD, Hering BJ, Beilman GJ, Dunn TB, et al.
Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg.
2012;214(4):409–24.
12. Conwell DL, Vargo JJ, Zuccaro G, Dews TE, Mekhail N, Scheman J, etal. Role of differential
neuroaxial blockade in the evaluation and management of pain in chronic pancreatitis. Am J
Gastroenterol. 2001;96(2):431–6.
13. Bahuva R, Walsh RM, Kapural L, Stevens T.Morphologic abnormalities are poorly predictive
of visceral pain in chronic pancreatitis. Pancreas. 2013;42(1):6–10.
14. Dasgupta A.Chapter 4—Alcohol biomarkers: an overview. In: Dasgupta A, editor. Alcohol and
its biomarkers. San Diego, CA: Elsevier; 2015. p.91–120. (Clinical Aspects and Laboratory
Determination) https://www.sciencedirect.com/science/article/pii/B9780128003398000043.
15. Morgan KA, Lancaster WP, Owczarski SM, Wang H, Borckardt J, Adams DB.Patient selection for total pancreatectomy with islet autotransplantation in the surgical management of
chronic pancreatitis. J Am Coll Surg. 2018;226(4):446–51.
16. Naples R, Walsh RM, Thomas JD, Perlmutter B, McMichael J, Augustin T, etal. Short- and
long-term surgical outcomes of total pancreatectomy with islet autotransplantation: a comparative analysis of surgical technique and intraoperative heparin dosing to optimize outcomes.
Pancreatology. 2021;21(1):291–8.
17. Johnston PC, Lin YK, Walsh RM, Bottino R, Stevens TK, Trucco M, etal. Factors associated with islet yield and insulin independence after total pancreatectomy and islet cell autotransplantation in patients with chronic pancreatitis utilizing off-site islet isolation: Cleveland
Clinic experience. J Clin Endocrinol Metab. 2015;100(5):1765–70.
18. Rickert C, Lei J, Markmann J.Islet autotransplantation for chronic pancreatitis. In: Current
surgical therapy. 12th ed. Elsevier Health Sciences. 2016.
19. Naples R, Perlmutter BC, Thomas JD, McMichael J, Bottino R, Solomina J, etal. Clinical
signicance of postoperative antibiotic treatment for positive islet cultures after total pancreatectomy with islet autotransplantation. Pancreas. 2021;50(7):1000–6.
20. Naziruddin B, Iwahashi S, Kanak MA, Takita M, Itoh T, Levy MF.Evidence for instant bloodmediated inammatory reaction in clinical autologous islet transplantation. Am J Transplant.
2014;14(2):428–37.
21. Fackche N, Walsh CM, Singh VK, Makary MA.Total pancreatectomy with islet autotransplantation. In: Current surgical therapy. 13th ed. Elsevier Health Sciences; 2020.
22. Edil BH, Cooper MA, Makary MA. Laparoscopic pancreaticojejunostomy using a barbed
suture: a novel technique. J Laparoendosc Adv Surg Tech. 2014;24(12):887–91.
23. Marquez S, Marquez TT, Ikramuddin S, Kandaswamy R, Antanavicius G, Freeman ML, etal.
Laparoscopic and da Vinci robot-assisted total pancreaticoduodenectomy and intraportal islet
autotransplantation: case report of a denitive minimally invasive treatment of chronic pancreatitis. Pancreas. 2010;39(7):1109–11.
24. Galvani CA, Rilo HR, Samamé J, Porubsky M, Rana A, Gruessner RWG. Fully roboticassisted technique for total pancreatectomy with an autologous islet transplant in chronic pancreatitis patients: results of a rst series. J Am Coll Surg. 2014;218(3):e73.
25. Zureikat AH, Nguyen T, Boone BA, Wijkstrom M, Hogg ME, Humar A, etal. Robotic total
pancreatectomy with or without autologous islet cell transplantation: replication of an open
technique through a minimal access approach. Surg Endosc. 2015;29(1):176–83.
169

170
26. Gołębiewska JE, etal. Assessment of simple indices based on a single fasting blood sample as
a tool to estimate beta-cell function after total pancreatectomy with islet autotransplantation—
a prospective study. Transpl Int. 2019;32(3):280–90. https://doi.org/10.1111/tri.13364.
27. Wilson GC, Sutton JM, Abbott DE, Smith MT, Lowy AM, Matthews JB, etal. Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation?
Ann Surg. 2014;260(4):659–67.
28. Fan CJ, Hirose K, Walsh CM, Quartuccio M, Desai NM, Singh VK, etal. Laparoscopic total
pancreatectomy with islet autotransplantation and intraoperative islet separation as a treatment
for patients with chronic pancreatitis. JAMA Surg. 2017;152(6):550–6.
29. Chung WS, Lin CL.Comorbid risks of deep vein thrombosis and pulmonary thromboembolism in patients with chronic pancreatitis: a nationwide cohort study. J Thromb Haemost.
2016;14(1):98–104.
30. Robbins AJ, Skube ME, Bellin MD, Dunn TB, Chapman SA, Berry KL, etal. Portal vein
thrombosis after total pancreatectomy and islet autotransplant: prophylaxis and graft impact.
Pancreas. 2019;48(10):1329–33.
31. Ahmad SA, Lowy AM, Wray CJ, D’Alessio D, Choe KA, James LE, etal. Factors associated
with insulin and narcotic independence after islet autotransplantation in patients with severe
chronic pancreatitis. J Am Coll Surg. 2005;201(5):680–7.
32. Webb MA, Illouz SC, Pollard CA, Gregory R, Mayberry JF, Tordoff SG, etal. Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function. Pancreas.
2008;37(3):282–7.
33. Chinnakotla S, Radosevich DM, Dunn TB, Bellin MD, Freeman ML, Schwarzenberg SJ, etal.
Long term outcomes of total pancreatectomy and islet auto transplantation for hereditary/
genetic pancreatitis. J Am Coll Surg. 2014;218(4):530–43.
34. Bellin MD, Beilman GJ, Sutherland DE, Ali H, Petersen A, Mongin S, etal. How durable is
total pancreatectomy and intraportal islet cell transplantation for treatment of chronic pancreatitis? J Am Coll Surg. 2019;228(4):329–39.
35. Barshes NR, Wyllie S, Goss JA.Inammation-mediated dysfunction and apoptosis in pancreatic
islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587–97.
36. Baldwin XL, Williams BM, Schrope B, Desai CS.What is new with total pancreatectomy
and autologous islet cell transplantation? Review of current progress in the eld. J Clin Med.
2021;10(10):2123.
37. Walsh RM, Saavedra JRA, Lentz G, Guerron AD, Scheman J, Stevens T, etal. Improved quality of life following total pancreatectomy and auto-islet transplantation for chronic pancreatitis. J Gastrointest Surg. 2012;16(8):1469–77.
38. Dorlon M, Owczarski S, Wang H, Adams D, Morgan K.Increase in postoperative insulin
requirements does not lead to decreased quality of life after total pancreatectomy with islet cell
autotransplantation for chronic pancreatitis. Am Surg. 2013;79(7):676–80.
J. Chang et al.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
